Lymphoblastoid alpha-interferon in the prevention of hepatocellular carcinoma (HCC) in high-risk HbsAg-positive resected cirrhotic HCC cases: A 14-year follow-up

Cancer Investigation

Volumn 21, Issue 3, 2003, Pages 394-399

  Oon, Chong Jin ^a   Chen, Wei Ning ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; LYMPHOBLAST INTERFERON; LYMPHOBLASTOID ALPHA INTERFERON; MITOMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MALE; PRECANCER; PRIORITY JOURNAL; RISK FACTOR;

EID: 0042358682     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120018231     Document Type: Article

References (16)

1. Parkin, D.M.; Muir, C.S.; Whelan, S.L.; Gao, Y-T.; Ferlay, J.; Powell, J. Cancer Incidence in Five Continents; IARC Scientific Publications: Lyon, 1992; Vol. 6.
2. Chen, M.F.; Jeng, L.B. Partial hepatic resection for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1997, 12, S329-S334.
3. Benvegnu, L.; Fattovich, G.; Noventa, F.; Tremolada, F.; Chemello, L.; Cechetto, A.; Alberti, A. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Cancer 1994, 74, 2442-2448.
4. Dorr, R.T. Interferon-α in malignant and viral diseases: an overview. Drugs 1993, 45, 177-211.
5. Daniels, H.M.; Meager, A.; Eddleston, A.L.; Alexander, G.J.; Williams, R. Spontaneous production of tumour necrosis factor α and interleukin-1 beta during interferon-α treatment of chronic HBV infection. Lancet 1990, 335, 875-877.
6. Hoofnagle, J.H.; Dusheiko, G.M.; Seeff, L.B.; Jones, E.A.; Waggoner, J.G.; Bales, Z.B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. 1981, 94, 744-748.
7. International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998, 351, 1535-1539.
8. Woo, M.H.; Burnakis, T.G. Interferon α in the treatment of chronic viral hepatitis B and C. Ann. Pharmacother. 1997, 31, 330-336.
9. Finter, N.B. The subtypes of α-interferon and their importance. In Proceedings of the 2nd International Symposium on Lymphob α-interferon, Barcelona, Spain; Dianzani, F., Valtuena, J.P., Eds.; 1994; 1-6.
10. Oon, C.J. Long term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high risk pre-cancerous conditions. Cancer Chemother. Pharmacol. 1992, 31, S137-S142.
11. Tsukuma, H.; Hiyama, T.; Tanaka, S.; Nakao, M.; Yabuuchi, T.; Kitamura, T.; Nakanishi, K.; Fujimoto, I.; Inoue, A.; Yamazaki, H. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 1993, 328, 1797-1801.
12. Castilla, A.; Prieto, J.; Fausto, N. Transforming growth factors β1 and α in chronic liver disease: effects of interferon α therapy. N. Engl. J. Med. 1991, 324, 933-940.
13. Lin, S.M.; Sheen, I.S.; Chien, R.N.; Chu, C.M.; Liaw, Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29, 971-975.
14. Harada, H.; Kitagawa, M.; Tanaka, N.; Yamamoto, H.; Harada, K.; Ishihara, M.; Taniguchi, T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993, 259, 971-974.
15. Ikeda, K.; Saitoh, S.; Suzuki, Y.; Kobayashi, M.; Tsubota, A.; Fukuda, M.; Koida, I.; Arase, Y.; Chayama, K.; Murashima, N.; Kumada, H. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus, a pilot study. Cancer 1998, 82, 827-835.
16. Yoshida, H.; Shiratori, Y.; Moriyama, M.; Arakawa, Y.; Ide, T.; Sata, M. ; Inoue, O.; Yano, M.; Tanaka, M.; Fujiyama, S.; Nishiguchi, S.; Kuroki, T.; Imazeki, F.; Yokosuka, O.; Kinoyama, S.; Yamada, G.; Omata, M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med. 1999, 131, 174-181.